Wyniki wyszukiwania:

The book involves a research work towards developing a formulation of anti-osteoporotic drug, which has in-vitro dissolution profile similar to that of the Innovators' formulation. The patents for dosage form of Raloxifene will expire in late future. Hence, our target was to develop a dosage form as that of Innovator product to file an ANDA application. The present study involves the development of a non-infringing formula for an orally administrable immediate release tablet of the anti-osteoporotic drug with reproducible and robust process. The objectives of the research work included (i)...